Mwb. Arush et al., ADVANCED NASOPHARYNGEAL CARCINOMA IN THE YOUNG - THE NORTHERN-ISRAEL-ONCOLOGY-CENTER EXPERIENCE, 1973-1991, Pediatric hematology and oncology, 12(3), 1995, pp. 271-276
Between 1973 and 1991, 10 patients with locally advanced [stages III a
nd IV] nasopharyngeal carcinoma were treated at the Northern Israel On
cology Center. All patients were treated with wide-field irradiation t
o the primary tumor, including the bare of skull, neck, and supraclavi
cular region. After 1984, 6 patients also received cisplatin/5FU-based
chemotherapy prior to radiotherapy and I patient received it after ra
diotherapy. All the patients who received chemotherapy are alive with
no evidence of disease, for a mean disease-free survival of 96 months
(range, 77 to 108 months), and no serious therapy-related late side-ef
fects have been noted, except in one patient. We conclude that adjuvan
t chemotherapy may be effective in improving outcome, but only randomi
zed prospective studies can evaluate its exact role.